Kerstin Mock
Overview
Explore the profile of Kerstin Mock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Preca B, Bajdak K, Mock K, Lehmann W, Sundararajan V, Bronsert P, et al.
Oncotarget
. 2017 Jan;
8(7):11530-11543.
PMID: 28086235
Cancer metastasis is the main reason for poor patient survival. Tumor cells delaminate from the primary tumor by induction of epithelial-mesenchymal transition (EMT). EMT is mediated by key transcription factors,...
2.
Lehmann W, Mossmann D, Kleemann J, Mock K, Meisinger C, Brummer T, et al.
Nat Commun
. 2016 Feb;
7:10498.
PMID: 26876920
Early dissemination, metastasis and therapy resistance are central hallmarks of aggressive cancer types and the leading cause of cancer-associated deaths. The EMT-inducing transcriptional repressor ZEB1 is a crucial stimulator of...
3.
Preca B, Bajdak K, Mock K, Sundararajan V, Pfannstiel J, Maurer J, et al.
Int J Cancer
. 2015 Jun;
137(11):2566-77.
PMID: 26077342
Invasion and metastasis of carcinomas are often activated by induction of aberrant epithelial-mesenchymal transition (EMT). This is mainly driven by the transcription factor ZEB1, promoting tumor-initiating capacity correlated with increased...
4.
Mock K, Preca B, Brummer T, Brabletz S, Stemmler M, Brabletz T
Oncotarget
. 2015 May;
6(16):14399-412.
PMID: 25973542
Tumor cell invasion, dissemination and metastasis is triggered by an aberrant activation of epithelial-to-mesenchymal transition (EMT), often mediated by the transcription factor ZEB1. Disseminating tumor cells must acquire specific features...
5.
Meidhof S, Brabletz S, Lehmann W, Preca B, Mock K, Ruh M, et al.
EMBO Mol Med
. 2015 Apr;
7(6):831-47.
PMID: 25872941
Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as...
6.
Vannier C, Mock K, Brabletz T, Driever W
J Biol Chem
. 2013 May;
288(26):18643-59.
PMID: 23667256
The ZEB1 transcription factor is best known as an inducer of epithelial-mesenchymal transitions (EMT) in cancer metastasis, acting through transcriptional repression of CDH1 (encoding E-cadherin) and the EMT-suppressing microRNA-200s (miR-200s)....